Easywell Biomedicals Inc.
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and … Read more
Easywell Biomedicals Inc. (1799) - Total Assets
Latest total assets as of June 2024: NT$1.40 Billion TWD
Based on the latest financial reports, Easywell Biomedicals Inc. (1799) holds total assets worth NT$1.40 Billion TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Easywell Biomedicals Inc. - Total Assets Trend (2019–2023)
This chart illustrates how Easywell Biomedicals Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Easywell Biomedicals Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Easywell Biomedicals Inc.'s total assets of NT$1.40 Billion consist of 41.8% current assets and 58.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 21.7% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$42.17 Million | 3.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Easywell Biomedicals Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Easywell Biomedicals Inc.'s current assets represent 41.8% of total assets in 2023, an increase from 27.8% in 2019.
- Cash Position: Cash and equivalents constituted 21.7% of total assets in 2023, up from 20.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 3.5% of total assets.
Easywell Biomedicals Inc. Competitors by Total Assets
Key competitors of Easywell Biomedicals Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Easywell Biomedicals Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Easywell Biomedicals Inc. generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Easywell Biomedicals Inc. is currently not profitable relative to its asset base.
Easywell Biomedicals Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.02 | 3.61 | 8.17 |
| Quick Ratio | 3.14 | 3.34 | 7.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$508.35 Million | NT$ 288.85 Million | NT$ 429.95 Million |
Easywell Biomedicals Inc. - Advanced Valuation Insights
This section examines the relationship between Easywell Biomedicals Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.10 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | NT$1.21 Billion |
| Market Capitalization | $62.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Easywell Biomedicals Inc.'s assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Easywell Biomedicals Inc.'s assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Easywell Biomedicals Inc. (2019–2023)
The table below shows the annual total assets of Easywell Biomedicals Inc. from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$1.21 Billion | +3.46% |
| 2022-12-31 | NT$1.17 Billion | -7.18% |
| 2021-12-31 | NT$1.26 Billion | +14.10% |
| 2020-12-31 | NT$1.11 Billion | -5.61% |
| 2019-12-31 | NT$1.17 Billion | -- |